A conference on “Development of high-tech medical services for cardiovascular patients in Russia” was held in the Russian Chamber of Commerce. The event gathered authorities from the Health Ministry, Ministry of Trade and Industry, private companies and professionals unions. Members of the conference discussed possible ways to improve quality and accessibility of medicines for cardiac patients.
During the conference Boehringer Ingelheim and ARPM member “Petrovax Pharm” signed an agreement to allocate in Russia a full cycle production of Tenektiplasa and Alteplaza for people with cardiovascular diseases.
To decrease the number of deaths related to cardiac diseases is one of the priorities of the Russian healthcare system. Cardiac conditions remain the primary cause of death in Russia. 63,000 of people died from myocardial infarction, and another 420,000 people had an ischemic stroke in 2015. To allocate production of cardiac medication and to increase people’s accessibility to theses medicines is a major factor in fighting death rate from cardiovascular diseases.
“Allocation of pharmaceutical production is one of the primary goals of the PHARMA-2020 strategy. However, the main concern on the state is safety and health of people. I am confident that the partnership between Boehringer Ingelheim and “Petrovax Pharm” will be working towards this goal,” said ARPM Director General, Victor Dmitriev.